{"id":20043,"date":"2023-04-04T22:42:00","date_gmt":"2023-04-04T14:42:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20043"},"modified":"2025-03-03T15:30:03","modified_gmt":"2025-03-03T07:30:03","slug":"biontech-and-duality-biologics-ink-exclusive-license-agreement-for-adc-assets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20043","title":{"rendered":"BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets"},"content":{"rendered":"\n

Germany-based BioNTech SE (NASDAQ: BNTX<\/a>) and China-headquartered Duality Biologics (Suzhou) Co., Ltd have announced that they have entered into exclusive license and collaboration agreements focused on two of Duality’s antibody-drug conjugate (ADC) assets. BioNTech is set to acquire all development, manufacturing, and commercialization rights to these two assets globally, excluding mainland China, Hong Kong, and Macau.<\/p>\n\n\n\n

Financial Terms and Milestones of the Agreement<\/strong>
Under the deal terms, Duality will receive upfront payments for both assets totaling USD 170 million, with the potential to receive additional development, regulatory, and commercial milestone payments for both assets, which could exceed USD 1.5 billion. Additionally, DualityBio will receive single- to double-digit tiered royalties on net sales for both assets.<\/p>\n\n\n\n

Commercial Rights and Collaboration Details<\/strong>
DualityBio retains commercial rights for mainland China, Hong Kong, and Macau. As part of the agreement for DB-1311, DualityBio has the right to exercise a co-development cost and profit\/loss sharing option for DB-1311 in the US market, as well as a co-promotion option for the US market.<\/p>\n\n\n\n

DB-1303 and DB-1311: Potent ADC Molecules with Broad Therapeutic Potential<\/strong>
DB-1303 is a third-generation HER2 ADC molecule built from DualityBio\u2019s proprietary Duality Immune Toxin Antibody Conjugates (DITAC) platform. The molecule has shown potent antitumor activity in both HER2-positive and HER2-low tumor models with a favorable safety profile and a potentially broad therapeutic window. Both preclinical data and preliminary clinical data from DB-1303 suggest the drug’s potential to address unmet medical needs in various HER2-expressing cancers.<\/p>\n\n\n\n

DB-1311 is an ADC comprised of a humanized antibody (target not disclosed) and DualityBio\u2019s proprietary DITAC linker-payload. It has exhibited potent antitumor activity in a range of tumor models representing multiple cancer types and has been well tolerated in preclinical studies, with a good pharmacokinetics profile. The wide therapeutic window demonstrated by preclinical antitumor activity and its safety profile supports the potential of DB-1311 to address unmet medical needs across a broad range of cancers.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Germany-based BioNTech SE (NASDAQ: BNTX) and China-headquartered Duality Biologics (Suzhou) Co., Ltd have announced that…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,342,16,232,3795,1124],"class_list":["post-20043","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-biontech","tag-cancer","tag-duality-biologics","tag-duality-biotherapeutics","tag-nasdaq-bntx"],"yoast_head":"\nBioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Germany-based BioNTech SE (NASDAQ: BNTX) and China-headquartered Duality Biologics (Suzhou) Co., Ltd have announced that they have entered into exclusive license and collaboration agreements focused on two of Duality's antibody-drug conjugate (ADC) assets. BioNTech is set to acquire all development, manufacturing, and commercialization rights to these two assets globally, excluding mainland China, Hong Kong, and Macau.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20043\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20043\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T14:42:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-03T07:30:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20043#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20043\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets\",\"datePublished\":\"2023-04-04T14:42:00+00:00\",\"dateModified\":\"2025-03-03T07:30:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20043\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"BioNTech\",\"Cancer\",\"Duality Biologics\",\"Duality Biotherapeutics\",\"NASDAQ: BNTX\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20043#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20043\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20043\",\"name\":\"BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-04T14:42:00+00:00\",\"dateModified\":\"2025-03-03T07:30:03+00:00\",\"description\":\"Germany-based BioNTech SE (NASDAQ: BNTX) and China-headquartered Duality Biologics (Suzhou) Co., Ltd have announced that they have entered into exclusive license and collaboration agreements focused on two of Duality's antibody-drug conjugate (ADC) assets. BioNTech is set to acquire all development, manufacturing, and commercialization rights to these two assets globally, excluding mainland China, Hong Kong, and Macau.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20043#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20043\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20043#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets - Insight, China's Pharmaceutical Industry","description":"Germany-based BioNTech SE (NASDAQ: BNTX) and China-headquartered Duality Biologics (Suzhou) Co., Ltd have announced that they have entered into exclusive license and collaboration agreements focused on two of Duality's antibody-drug conjugate (ADC) assets. BioNTech is set to acquire all development, manufacturing, and commercialization rights to these two assets globally, excluding mainland China, Hong Kong, and Macau.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20043","og_locale":"en_US","og_type":"article","og_title":"BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20043","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-04T14:42:00+00:00","article_modified_time":"2025-03-03T07:30:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20043#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20043"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets","datePublished":"2023-04-04T14:42:00+00:00","dateModified":"2025-03-03T07:30:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20043"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","BioNTech","Cancer","Duality Biologics","Duality Biotherapeutics","NASDAQ: BNTX"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20043#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20043","url":"https:\/\/flcube.com\/?p=20043","name":"BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-04T14:42:00+00:00","dateModified":"2025-03-03T07:30:03+00:00","description":"Germany-based BioNTech SE (NASDAQ: BNTX) and China-headquartered Duality Biologics (Suzhou) Co., Ltd have announced that they have entered into exclusive license and collaboration agreements focused on two of Duality's antibody-drug conjugate (ADC) assets. BioNTech is set to acquire all development, manufacturing, and commercialization rights to these two assets globally, excluding mainland China, Hong Kong, and Macau.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20043#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20043"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20043#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20043"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20043\/revisions"}],"predecessor-version":[{"id":20044,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20043\/revisions\/20044"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}